Novo Nordisk highlights strong cardiometabolic performance of Saxenda

Novo Nordisk has announced new clinical trial results showing how treatment with Saxenda can lead to improvements in cardiometabolic risk factors.

Data from the three-year part of the phase IIIa SCALE obesity and prediabetes trial have been presented, demonstrating that 160 weeks of treatment with Saxenda in combination with a reduced-calorie diet and increased physical activity can help lower blood pressure and cholesterol.

Significant improvements were seen compared to placebo, with individuals treated with Saxenda losing more weight, reducing their mean waist circumference and seeing greater improvements in triglycerides.

The drug was able to meet its primary endpoint in the trial, with continued treatment over three years with Saxenda helping to delay the onset of type 2 diabetes compared with placebo.

Trial investigator Dr Ken Fujioka of the Scripps Clinic in San Diego, said: "This is currently the longest weight management trial with Saxenda, and the observed improvements in blood pressure, lipids and waist circumference at three years are encouraging."

Saxenda was approved in Europe for the treatment of obesity last year.